84 related articles for article (PubMed ID: 1155469)
1. Fat emulsion vehicle for intravenous administration of an aqueous insoluble drug.
Fortner CL; Grove WR; Bowie D; Walker MD
Am J Hosp Pharm; 1975 Jun; 32(6):582-4. PubMed ID: 1155469
[TBL] [Abstract][Full Text] [Related]
2. Formulation of three nitrosoureas for intravenous use.
Davignon JP; Yang KW; Wood HB; Cradock JC
Cancer Chemother Rep 3; 1973 May; 4(3):7-11. PubMed ID: 4201309
[No Abstract] [Full Text] [Related]
3. Parenteral formulation of hexamethylmelamine potentially suitable for use in man.
Ames MM; Kovach JS
Cancer Treat Rep; 1982 Jul; 66(7):1579-81. PubMed ID: 6807543
[TBL] [Abstract][Full Text] [Related]
4. Distribution of 14C-lomustine (14C-CCNU)-derived radioactivity following intravenous administration of three potential clinical formulations to rabbits.
Litterst CL; Mimnaugh EG; Cowles AC; Gram TE; Guarino AM
J Pharm Sci; 1974 Nov; 63(11):1718-21. PubMed ID: 4427229
[No Abstract] [Full Text] [Related]
5. Cause of variability in activity of samples of CCNU against P388 leukemia in vivo.
Montgomery JA
Cancer Treat Rep; 1980; 64(8-9):987-91. PubMed ID: 7448833
[No Abstract] [Full Text] [Related]
6. The use of oil-in-water emulsions as a vehicle for parenteral drug administration.
Prankerd RJ; Stella VJ
J Parenter Sci Technol; 1990; 44(3):139-49. PubMed ID: 2196363
[TBL] [Abstract][Full Text] [Related]
7. Bacterial and fungal growth in intravenous fat emulsions.
Kim CH; Lewis DE; Kumar A
Am J Hosp Pharm; 1983 Dec; 40(12):2159-61. PubMed ID: 6660230
[TBL] [Abstract][Full Text] [Related]
8. Salvage chemotherapy for non-Hodgkin's lymphoma.
Ng PR; Todd D; Khoo RK
Cancer Treat Rep; 1982 Nov; 66(11):1977-9. PubMed ID: 7139640
[TBL] [Abstract][Full Text] [Related]
9. Effects of temperature and handling conditions on lipid emulsion stability in veterinary parenteral nutrition admixtures during simulated intravenous administration.
Thomovsky EJ; Backus RC; Mann FA; Richmond CK; Wagner-Mann CC
Am J Vet Res; 2008 May; 69(5):652-8. PubMed ID: 18447797
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of beta-2'-deoxythioguanosine combined with methyl-CCNU or mitomycin in advanced colorectal cancer. A Southwest Oncology Group study.
Gagliano RG; Panettiere FJ; Haas CD; Baker L; Hewlett J; Stuckey WJ; O'Bryan RM; Bottomley R; Heilburn LK
Cancer Clin Trials; 1981; 4(4):401-5. PubMed ID: 7318121
[TBL] [Abstract][Full Text] [Related]
11. Combination chemotherapy with VM 26 and CCNU in primary malignant brain tumors of children.
Seiler RW
Helv Paediatr Acta; 1980 Mar; 35(1):51-6. PubMed ID: 7410103
[TBL] [Abstract][Full Text] [Related]
12. The nitrosoureas: an outline of clinical schedules and toxic effects.
Wasserman TH
Cancer Treat Rep; 1976 Jun; 60(6):709-11. PubMed ID: 954008
[No Abstract] [Full Text] [Related]
13. Formulation, stability and degradation kinetics of intravenous cinnarizine lipid emulsion.
Shi S; Chen H; Cui Y; Tang X
Int J Pharm; 2009 May; 373(1-2):147-55. PubMed ID: 19429300
[TBL] [Abstract][Full Text] [Related]
14. Randomized study for the treatment of adult advanced Hodgkin's disease: mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) versus lomustine, vinblastine, and prednisone.
Liebman HA; Hum GJ; Sheehan WW; Ryden VM; Bateman JR
Cancer Treat Rep; 1983 May; 67(5):413-9. PubMed ID: 6342771
[TBL] [Abstract][Full Text] [Related]
15. Etretinate, lomustine, and bleomycin versus lomustine and bleomycin in advanced squamous cell lung carcinoma.
Weber W; Obrecht JP
Cancer Treat Rep; 1983 Sep; 67(9):847-9. PubMed ID: 6192913
[No Abstract] [Full Text] [Related]
16. Further methodological studies on the intravenous fat tolerance with Intralipid emulsion.
Rössner S
Scand J Clin Lab Invest; 1976 Mar; 36(2):155-9. PubMed ID: 1273493
[TBL] [Abstract][Full Text] [Related]
17. [Preparation and quality evaluation of intravenous tanshinone II (A) emulsion].
Liang Z; Mao SJ; Yin ZN; Jin H; Li H; Chu T
Zhongguo Zhong Yao Za Zhi; 2008 Jun; 33(11):1249-52. PubMed ID: 18831197
[TBL] [Abstract][Full Text] [Related]
18. A new formulation concept for drugs with poor water solubility for parenteral application.
Jürgens K; Müller BW
Pharmazie; 2005 Sep; 60(9):665-70. PubMed ID: 16222865
[TBL] [Abstract][Full Text] [Related]
19. Effect of partition coefficient on the ability of nitroimidazoles to enhance the cytotoxicity of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea.
Hirst DG; Brown JM; Hazlehurst JL
Cancer Res; 1983 May; 43(5):1961-5. PubMed ID: 6682009
[TBL] [Abstract][Full Text] [Related]
20. Improved delivery through biological membranes. XLV. Synthesis, physical-chemical evaluation, and brain uptake studies of 2-chloroethyl nitrosourea delivery systems.
Raghavan K; Loftsson T; Brewster ME; Bodor N
Pharm Res; 1992 Jun; 9(6):743-9. PubMed ID: 1409355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
